

# CITATION REPORT

List of articles citing

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders

DOI: 10.3233/jad-2006-9309

Journal of Alzheimer's Disease, 2006, 9, 293-348.

**Source:** <https://exaly.com/paper-pdf/40279536/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
346	Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach. <b>2006</b> , 5, 2769-79		85
345	CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. <b>2006</b> , 251, 124-8		41
344	Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. <b>2006</b> , 52, 33-8		360
343	Potential applications and limitations of proteomics in the study of neurological disease. <b>2006</b> , 63, 1692-6		12
342	Biomarkers for Alzheimer's disease. <b>2007</b> , 7, 1021-8		11
341	Proteomics identification of proteins in human cortex using multidimensional separations and MALDI tandem mass spectrometer. <b>2007</b> , 6, 1818-23		40
340	Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity. <b>2007</b> , 282, 36987-97		19
339	Cerebrospinal Fluid Proteomes: From Neural Development to Neurodegenerative Diseases. <b>2007</b> , 4, 89-106		13
338	Application of proteomic technology to neural stem cell science and neurology. <b>2007</b> , 2, 285-296		
337	Serum biomarkers for Alzheimer's disease: proteomic discovery. <b>2007</b> , 61, 383-9		42
336	Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. <b>2007</b> , 6, 2565-75		55
335	Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. <b>2007</b> , 4, 227-38		40
334	Biomarkers for Alzheimer's disease. <b>2007</b> , 7, 635-46		23
333	Proteomic discovery of CSF biomarkers for Alzheimer's disease. <b>2007</b> , 61, 497; author reply 497-8		4
332	Reply: Cerebrospinal fluid proteomics for biomarkers of Alzheimer's disease. <b>2007</b> , 61, 497-498		4
331	Reply: Mathematical modeling and complexity of biological behavior of low-grade gliomas. <b>2007</b> , 61, 496-497		3
330	Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis. <b>2007</b> , 1, 467-75		22

329	Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. <b>2007</b> , 1, 1373-84	47
328	Proteomics of human cerebrospinal fluid - the good, the bad, and the ugly. <b>2007</b> , 1, 805-19	42
327	A better understanding of molecular mechanisms underlying human disease. <b>2007</b> , 1, 983-1003	15
326	A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. <b>2007</b> , 7, 469-73	100
325	Proteomic identification of novel proteins in cortical lewy bodies. <b>2007</b> , 17, 139-45	163
324	Metabolomic analysis of urine and serum in Parkinson's disease. <b>2008</b> , 4, 191-201	79
323	Apport des biomarqueurs au diagnostic de la maladie de Parkinson. <b>2008</b> , 28, 34-37	
322	Neuroproteomics as a promising tool in Parkinson's disease research. <b>2008</b> , 115, 1413-30	22
321	Identification of proteins in human substantia nigra. <b>2008</b> , 2, 776-82	27
320	Proteomic identification of proteins in the human brain: Towards a more comprehensive understanding of neurodegenerative disease. <b>2008</b> , 2, 1484-97	17
319	Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research. <b>2008</b> , 43, 559-71	36
318	Pharmacokinetics in drug discovery. <b>2008</b> , 97, 654-90	81
317	Amine-reactive isobaric tagging reagents: requirements for absolute quantification of proteins and peptides. <b>2008</b> , 379, 164-9	30
316	Integrated analysis of the cerebrospinal fluid peptidome and proteome. <b>2008</b> , 7, 386-99	148
315	Applications of proteomics to lab diagnosis. <b>2008</b> , 3, 485-98	33
314	Clinical proteomics in neurodegenerative disorders. <b>2008</b> , 118, 1-11	51
313	Serum biomarker profiling in cancer studies: a question of standardisation?. <b>2008</b> , 6, 224-47	18
312	The proteogenomic path towards biomarker discovery. <b>2008</b> , 12, 737-47	45

311	Biomarkers for cognitive impairment and dementia in elderly people. <b>2008</b> , 7, 704-14	64
310	Biomarkers for early diagnosis of Alzheimer disease: 'ALzheimer ASsociated gene'--a new blood biomarker?. <b>2008</b> , 12, 1094-117	37
309	Potential Proteomic-Based Strategies for Understanding Laminitis: Predictions and Pathogenesis. <b>2008</b> , 28, 484-487	4
308	Psychiatric research: psychoproteomics, degradomics and systems biology. <b>2008</b> , 5, 293-314	31
307	Proteomics of human neurodegenerative diseases. <b>2008</b> , 67, 923-32	29
306	iTRAQ experimental design for plasma biomarker discovery. <b>2008</b> , 7, 2952-8	96
305	Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. <b>2008</b> , 7, 720-30	59
304	Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid. <b>2008</b> , 7, 4409-21	43
303	Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. <b>2008</b> , 25, 195-205	28
302	Biomarker identification for diagnosis of Alzheimer's disease. <b>2008</b> , 2, 577-91	5
301	Mass spectrometry-based neurochemical analysis: perspectives for primate research. <b>2008</b> , 5, 641-52	7
300	CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. <b>2008</b> , 129, 526-9	222
299	Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 14, 17-25	4-3 85
298	Mortalin: a protein associated with progression of Parkinson disease?. <b>2008</b> , 67, 117-24	69
297	Modified Enrichment Method for Identification of Human Cerebrospinal Fluid Proteins by Mass Spectrometry. <b>2009</b> , 6, 154-178	
296	New perspectives for the diagnosis of Alzheimer's disease. <b>2009</b> , 4, 160-81	11
295	Biomarker discovery in neurodegenerative diseases: a proteomic approach. <b>2009</b> , 35, 157-64	88
294	Biomarkers of Alzheimer's disease. <b>2009</b> , 35, 128-40	134

293	Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. <b>2009</b> , 1265, 158-70		95
292	Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. <b>2009</b> , 87, 2578-90		32
291	The role of proteomics in dementia and Alzheimer's disease. <b>2009</b> , 118, 181-95		47
290	Proteomic Profiling of Cerebrospinal Fluid by 8-Plex iTRAQ Reveals Potential Biomarker Candidates of Alzheimer's Disease. <i>Clinical Proteomics</i> , <b>2009</b> , 5, 114-124	5	3
289	Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. <b>2009</b> , 19, 1401-3		29
288	Biomarkers in Huntington's and Parkinson's Disease. <b>2009</b> , 1180, 97-110		21
287	Proteomics in human Parkinson's disease research. <b>2009</b> , 73, 10-29		85
286	Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. <b>2009</b> , 405, 143-7		20
285	Abnormal serum concentrations of proteins in Parkinson's disease. <b>2009</b> , 389, 321-7		17
284	Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. <b>2009</b> , 15, 205-12		44
283	Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. <b>2009</b> , 16, 90-3		30
282	Potential markers of preeclampsia--a review. <b>2009</b> , 7, 70		184
281	Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys. <b>2009</b> , 8, 2253-60		30
280	Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. <b>2009</b> , 175, 54-65		73
279	Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. <b>2009</b> , 15, 157-82		29
278	Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. <b>2009</b> , 8, 3497-511		73
277	Deconvoluting the 'omics' for organ transplantation. <b>2009</b> , 14, 544-51		24
276	Interpreting the proteome and peptidome in transplantation. <b>2009</b> , 47, 139-69		17

275	Advances in Quantitative Mass Spectrometry Analysis: Weighing in on Isotope Coding and Label-Free Approaches for Expression and Functional Proteomics. <b>2009</b> , 5, 166-185		2
274	Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 19, 301-9	4-3	16
273	Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 21, 585-96	4-3	58
272	Recent cerebrospinal fluid biomarker studies of Alzheimer's disease. <b>2010</b> , 7, 919-29		20
271	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. <b>2010</b> , 120, 385-99		65
270	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. <b>2010</b> , 39, 229-41		56
269	Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease. <b>2010</b> , 45, 57-63		36
268	Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects. <b>2010</b> , 45, 5-14		103
267	Glycoproteomics in neurodegenerative diseases. <b>2010</b> , 29, 79-125		75
266	Assessment of the partitioning capacity of high abundant proteins in human cerebrospinal fluid using affinity and immunoaffinity subtraction spin columns. <b>2010</b> , 878, 1519-30		17
265	A multiplexed quantitative proteomics approach for investigating protein expression in the developing central nervous system. <b>2010</b> , 191, 75-82		8
264	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldt-Jakob disease. <b>2010</b> , 10, 81-9		35
263	MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. <b>2010</b> , 24, 403-8		6
262	Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. <b>2010</b> , 17, 456-60		19
261	An update on clinical proteomics in Alzheimer's research. <b>2010</b> , 112, 1386-414		70
260	Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. <b>2010</b> , 122, 350-9		41
259	Biomarkers for cognitive impairment in Parkinson disease. <b>2010</b> , 20, 660-71		25
258	Cerebrospinal fluid biomarkers for dementia with lewy bodies. <b>2010</b> , 2010, 536538		19

257	In-depth exploration of cerebrospinal fluid by combining peptide ligand library treatment and label-free protein quantification. <b>2010</b> , 9, 1006-21		106
256	Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. <b>2010</b> , 10, 1035-50		10
255	Proteomic profiling of cerebrospinal fluid in Creutzfeldt-Jakob disease. <b>2010</b> , 7, 907-17		13
254	Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease. <b>2010</b> , 10, 925-42		63
253	Problems associated with fluid biomarkers for Parkinson's disease. <b>2010</b> , 4, 671-81		13
252	Misfolded proteins and neurodegeneration: role of non-native cytochrome c in cell death. <b>2010</b> , 7, 507-17		32
251	Isobaric tagging-based selection and quantitation of cerebrospinal fluid tryptic peptides with reporter calibration curves. <b>2010</b> , 82, 848-58		45
250	Quantitative proteomic analysis of oligodendrogliomas with and without 1p/19q deletion. <b>2010</b> , 9, 2610-8		12
249	Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy. <b>2010</b> , 7, 565-78		14
248	Proteomic analysis of expression and protein interactions in a 6-hydroxydopamine-induced rat brain lesion model. <b>2010</b> , 57, 16-32		22
247	Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. <b>2010</b> , 16, 307-15		23
246	Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. <b>2010</b> , 16, 545-9		36
245	Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers. <b>2010</b> , 7, 263-74		19
244	A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. <i>PLoS ONE</i> , <b>2011</b> , 6, e28092	3.7	109
243	Proteomic research in psychiatry. <b>2011</b> , 25, 151-96		68
242	Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer's disease and other dementias. <b>2011</b> , 16, 161-71		18
241	Biomarkers of Parkinson's disease and Dementia with Lewy bodies. <b>2011</b> , 95, 601-13		27
240	Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. <i>Neuroscience</i> , <b>2011</b> , 180, 256-71	3.9	40

239	Functional proteogenomics--embracing complexity. <b>2011</b> , 23, 235-51		18
238	Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies. <b>2011</b> , 156, 325-37		19
237	Bridging molecular genetics and biomarkers in lewy body and related disorders. <b>2011</b> , 2011, 842475		5
236	Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e16032	3.7	124
235	Partial loss of parvalbumin-containing hippocampal interneurons in dementia with Lewy bodies. <b>2011</b> , 31, 1-10		18
234	Identifying and validating biomarkers for Alzheimer's disease. <b>2011</b> , 29, 26-32		321
233	Quest for new genomic and proteomic biomarkers in neurology. <b>2011</b> , 2,		
232	Functional analysis of proteins and protein species using shotgun proteomics and linear mathematics. <b>2011</b> , 41, 329-41		8
231	Analysis of membrane and hydrophilic proteins simultaneously derived from the mouse brain using cloud-point extraction. <b>2011</b> , 400, 2827-36		25
230	Spectral counting assessment of protein dynamic range in cerebrospinal fluid following depletion with plasma-designed immunoaffinity columns. <i>Clinical Proteomics</i> , <b>2011</b> , 8, 6	5	17
229	Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. <b>2011</b> , 74, 371-88		107
228	Positional integratomic approach in identification of genomic candidate regions for Parkinson's disease. <b>2011</b> , 27, 1971-8		9
227	Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease. <b>2012</b> , 2012, 824024		8
226	Proteomic analysis of cerebrospinal fluid in a fulminant case of multiple sclerosis. <b>2012</b> , 13, 7676-93		21
225	Plasma levels of complement 4a protein are increased in Alzheimer's disease. <b>2012</b> , 26, 329-34		26
224	Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. <b>2012</b> , 69, 96-104		92
223	Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. <b>2012</b> , 6, 455-76		83
222	Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. <b>2012</b> , 15, 1413-25		79

221	Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. <b>2012</b> , 34, 669-76		47
220	Transthyretin decrease in plasma of MCI and AD patients: investigation of mechanisms for disease modulation. <b>2012</b> , 9, 881-9		34
219	Biomarkers for Alzheimer's disease: showing the way or leading us astray?. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33 Suppl 1, S371-6	4-3	4
218	Proteins in aqueous humor from cataract patients with and without pseudoexfoliation syndrome. <b>2012</b> , 18, 531-41		16
217	Use of proteomic methods in the analysis of human body fluids in Alzheimer research. <b>2012</b> , 33, 3617-30		30
216	Applying bioinformatics to proteomics: is machine learning the answer to biomarker discovery for PD and MSA?. <b>2012</b> , 27, 1595-7		8
215	A novel peptidomics approach to detect markers of Alzheimer's disease in cerebrospinal fluid. <b>2012</b> , 56, 500-7		36
214	Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains. <b>2012</b> , 11, 3053-67		104
213	Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. <b>2012</b> , 159B, 874-83		11
212	Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 28, 625-36	4-3	49
211	The proteomic toolbox for studying cerebrospinal fluid. <b>2012</b> , 9, 165-79		18
210	Quantitative Proteomics Using iTRAQ Labeling and Mass Spectrometry. <b>2012</b> ,		2
209	Anatomic and clinical pathology of cognitive impairment and dementia. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33 Suppl 1, S181-4	4-3	4
208	To label or not to label: applications of quantitative proteomics in neuroscience research. <b>2012</b> , 12, 736-47		52
207	Premotor Parkinson's disease: concepts and definitions. <b>2012</b> , 27, 608-16		108
206	Biochemical premotor biomarkers for Parkinson's disease. <b>2012</b> , 27, 644-50		26
205	Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy. <b>2012</b> , 27, 851-7		21
204	Statistical considerations of optimal study design for human plasma proteomics and biomarker discovery. <b>2012</b> , 11, 2103-13		45

203	An Overview of Endogenous Catechol-Isoquinolines and Their Related Enzymes: Possible Biomarkers for Parkinson's Disease. <b>2012</b> , 1, 59-67	4
202	Comparative proteome analysis of peripheral blood mononuclear cells in systemic lupus erythematosus with iTRAQ quantitative proteomics. <b>2012</b> , 32, 585-93	28
201	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. <b>2012</b> , 119, 39-52	54
200	Blood and plasma-based proteomic biomarker research in Alzheimer's disease. <b>2013</b> , 101-102, 1-17	88
199	Genetic Variants in Alzheimer's Disease. <b>2013</b> ,	8
198	Glia-based biomarkers and their functional role in the CNS. <b>2013</b> , 10, 43-63	15
197	PanelomiX: A threshold-based algorithm to create panels of biomarkers. <b>2013</b> , 1, 57-64	22
196	Biomarkers of Neurological Disorders. <b>2013</b> , 49-153	
195	Top-down mass spectrometry on tissue extracts and biofluids with isoelectric focusing and superficially porous silica liquid chromatography. <b>2013</b> , 85, 10377-84	21
194	Neurodegenerative Diseases: Integrative PPM Approach as the Medicine of the Future. <b>2013</b> ,	3
193	Alzheimer's disease biomarkers: correspondence between human studies and animal models. <b>2013</b> , 56, 116-30	15
192	Comparative study of label and label-free techniques using shotgun proteomics for relative protein quantification. <b>2013</b> , 928, 83-92	22
191	Parkinson's Disease. <b>2013</b> , 1034-1043	
190	Biomarkers of Parkinson's disease: current status and future perspectives. <b>2013</b> , 18, 155-62	36
189	Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression. <i>Neuroscience</i> , <b>2013</b> , 247, 191-200	3.9 69
188	Translational proteomics in Alzheimer's disease and related disorders. <b>2013</b> , 46, 480-6	17
187	Biological and methodical challenges of blood-based proteomics in the field of neurological research. <b>2013</b> , 101-102, 18-34	38
186	Vitamin D-binding protein interacts with A $\beta$ and suppresses A $\beta$ -mediated pathology. <b>2013</b> , 20, 630-8	56

185	MALDI imaging of post-mortem human spinal cord in amyotrophic lateral sclerosis. <b>2013</b> , 124, 695-707		42
184	Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. <b>2013</b> , 930, 129-35		38
183	Biomarkers in Parkinson's disease (recent update). <b>2013</b> , 63, 201-29		147
182	An Update on CSF Biomarkers of Parkinson's Disease. <b>2013</b> , 161-184		4
181	Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies. <b>2013</b> , 5, 2837-56		35
180	Tear fluid protein biomarkers. <b>2013</b> , 62, 151-96		28
179	High blood pressure effects on the blood to cerebrospinal fluid barrier and cerebrospinal fluid protein composition: a two-dimensional electrophoresis study in spontaneously hypertensive rats. <b>2013</b> , 2013, 164653		10
178	Secretory sorting receptors carboxypeptidase E and secretogranin III in amyloid $\beta$ -associated neural degeneration in Alzheimer's disease. <b>2013</b> , 23, 274-84		30
177	Elevated levels of multiple biomarkers of Alzheimer's disease in the aqueous humor of eyes with open-angle glaucoma. <b>2013</b> , 54, 5353-8		56
176	Neurogenomic and Neuroproteomic Approaches to Studying Neural Injury. <b>2013</b> ,		
175	Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 34, 387-97	4-3	6
174	Cerebrospinal fluid biomarker candidates for parkinsonian disorders. <b>2012</b> , 3, 187		20
173	Cerebrospinal fluid biomarker candidates associated with human WNV neuroinvasive disease. <i>PLoS ONE</i> , <b>2014</b> , 9, e93637	3-7	5
172	Biomarkers in biological fluids for dementia with Lewy bodies. <b>2014</b> , 6, 72		24
171	Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. <b>2014</b> , 15, 7865-82		39
170	Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. <b>2014</b> , 85, 1065-75		63
169	Proteomics as a new paradigm to tackle Parkinson's disease research challenges. <b>2014</b> , 4-5, 1-17		9
168	Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 43, 1355-73	4-3	56

167	Discovery and identification of serum potential biomarkers for pulmonary tuberculosis using iTRAQ-coupled two-dimensional LC-MS/MS. <b>2014</b> , 14, 322-31	62
166	Altered levels of amyloid precursor protein intracellular domain-interacting proteins in Alzheimer disease. <b>2014</b> , 28, 283-90	8
165	Oxidative post-translational modifications develop LONP1 dysfunction in pressure overload heart failure. <b>2014</b> , 7, 500-9	44
164	Blood and cerebrospinal fluid markers in Parkinson's disease: current biomarker findings. <b>2014</b> , 1	4
163	Role of proteomics in biomarker discovery: prognosis and diagnosis of neuropsychiatric disorders. <b>2014</b> , 94, 39-75	14
162	Vitamin D binding protein: a multifunctional protein of clinical importance. <b>2014</b> , 63, 1-57	76
161	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <b>2014</b> , 261, 1234-43	29
160	In-depth characterization of the cerebrospinal fluid (CSF) proteome displayed through the CSF proteome resource (CSF-PR). <b>2014</b> , 13, 3152-63	97
159	Refined microdialysis method for protein biomarker sampling in acute brain injury in the neurointensive care setting. <b>2014</b> , 86, 8671-9	29
158	Global in vivo terminal amino acid labeling for exploring differential expressed proteins induced by dialyzed serum cultivation. <b>2014</b> , 139, 4497-504	6
157	A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease. <b>2014</b> , 128, 419-30	27
156	Vitamin D binding protein as a serum biomarker of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 43, 37-45	4-3 25
155	Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. <b>2014</b> , 9, 22	90
154	Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas. <b>2014</b> , 37, 367-80; discussion 380	38
153	Chromosome-centric human proteome project: deciphering proteins associated with glioma and neurodegenerative disorders on chromosome 12. <b>2014</b> , 13, 3178-90	18
152	Proteomics. <b>2014</b> , 147-179	5
151	A multiple-reaction-monitoring mass spectrometric method for simultaneous quantitative analysis of five plasma apolipoproteins. <b>2014</b> , 57, 723-731	2
150	A review of vitamin D and Parkinson's disease. <b>2014</b> , 78, 40-4	27

149	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. <b>2014</b> , 35, 614-22	36
148	Proteomic analysis of saliva from patients with oral chronic graft-versus-host disease. <b>2014</b> , 20, 1048-55	26
147	Tau protein, beta-amyloid and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. <b>2014</b> , 343, 120-4	44
146	Quantitative proteomic analysis of Down syndrome in the umbilical cord blood using iTRAQ. <b>2015</b> , 11, 1391-9	11
145	Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. <b>2015</b> , 5, 17559	32
144	Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies. <b>2015</b> , 6, 39437-56	50
143	Specific alterations in plasma proteins during depressed, manic, and euthymic states of bipolar disorder. <b>2015</b> , 48, 973-82	29
142	An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. <b>2015</b> , 14, 654-63	65
141	'Vitamin D and cognition in older adults': updated international recommendations. <b>2015</b> , 277, 45-57	95
140	Explorative and targeted neuroproteomics in Alzheimer's disease. <b>2015</b> , 1854, 769-78	36
139	A rapid method for preparation of the cerebrospinal fluid proteome. <b>2015</b> , 15, 10-5	6
138	Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases. <b>2015</b> , 121, 59-86	5
137	Approaches for targeted proteomics and its potential applications in neuroscience. <b>2015</b> , 40, 607-27	17
136	Stable isotope labelling methods in mass spectrometry-based quantitative proteomics. <b>2015</b> , 113, 2-20	184
135	Blood, sweat, and tears: developing clinically relevant protein biosensors for integrated body fluid analysis. <b>2015</b> , 140, 4350-64	117
134	Identification of the soluble form of tyrosine kinase receptor Axl as a potential biomarker for intracranial aneurysm rupture. <b>2015</b> , 15, 23	10
133	Serum peptides as candidate biomarkers for dementia with Lewy bodies. <b>2015</b> , 30, 1195-206	7
132	Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. <b>2015</b> , 14, 544-55	42

131	Proteomic profiling in MPTP monkey model for early Parkinson disease biomarker discovery. <b>2015</b> , 1854, 779-87	21
130	Identification and validation of argininosuccinate synthase as a candidate urinary biomarker for major depressive disorder. <b>2015</b> , 451, 142-8	8
129	Proteomics discovery of radioresistant cancer biomarkers for radiotherapy. <b>2015</b> , 369, 289-97	17
128	Elevated host lipid metabolism revealed by iTRAQ-based quantitative proteomic analysis of cerebrospinal fluid of tuberculous meningitis patients. <b>2015</b> , 466, 689-95	14
127	Chaperones in Neurodegeneration. <b>2015</b> , 35, 13853-9	62
126	Proteomics of Cerebrospinal Fluid: Throughput and Robustness Using a Scalable Automated Analysis Pipeline for Biomarker Discovery. <b>2015</b> , 87, 10755-61	26
125	Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease. <b>2015</b> , 74, 32-40	4
124	Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease. 231-241	
123	Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease. 249-264	
122	Proteomics and Human Diseases. <b>2016</b> , 09,	5
121	Vitamin D and cognition in older adults: international consensus guidelines. <b>2016</b> , 14, 265-73	11
120	PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimers Disease</i> , <b>2016</b> , 53, 1563-76	4-3 18
119	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. <b>2016</b> , 31, 848-60	40
118	Neuroproteomic profiling of human body fluids. <b>2016</b> , 10, 485-502	6
117	The neural chaperone proSAAS blocks $\alpha$ -synuclein fibrillation and neurotoxicity. <b>2016</b> , 113, E4708-15	23
116	Genome-wide significant results identified for plasma apolipoprotein H levels in middle-aged and older adults. <b>2016</b> , 6, 23675	13
115	Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?. <b>2016</b> , 15, 409-25	57
114	Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry. <b>2016</b> , 139, 103-21	35

113	Differential expression of serum proteins in rats subchronically exposed to arsenic identified by iTRAQ-based proteomic technology-14-3-3 protein to serve as a potential biomarker. <b>2016</b> , 5, 651-659			5
112	Quantitative Proteomic Analysis Reveals Molecular Adaptations in the Hippocampal Synaptic Active Zone of Chronic Mild Stress-Unsusceptible Rats. <b>2015</b> , 19,			21
111	Statistical Analysis in Proteomics. <i>Methods in Molecular Biology</i> , <b>2016</b> ,	1.4		1
110	Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease. <b>2016</b> , 39, 390-7			3
109	GC and VDR SNPs and Vitamin D Levels in Parkinson's Disease: The Relevance to Clinical Features. <b>2017</b> , 19, 24-40			29
108	The Search for a Peripheral Biopsy Indicator of Synuclein Pathology for Parkinson Disease. <b>2017</b> , 76, 2-15			50
107	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. <b>2017</b> , 37, 65-71			24
106	Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid. <b>2017</b> , 54, 185-204			18
105	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1598, 101-115	1.4		11
104	Variations in the cerebrospinal fluid proteome following traumatic brain injury and subarachnoid hemorrhage. <b>2017</b> , 24, 169-183			17
103	Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. <b>2017</b> , 974, 21-48			20
102	Proteomic Biomarker Identification in Cerebrospinal Fluid for Leptomeningeal Metastases with Neurological Complications. <b>2017</b> , 974, 85-96			2
101	Serum quantitative proteomic analysis of patients with keshan disease based on iTRAQ labeling technique: A first term study. <b>2017</b> , 44, 331-338			10
100	Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications. <b>2017</b> , 14, 997-1006			6
99	Recent progress in mass spectrometry proteomics for biomedical research. <b>2017</b> , 60, 1093-1113			52
98	Decreased Neuro-Axonal Proteins in CSF at First Attack of Suspected Multiple Sclerosis. <b>2017</b> , 11, 1700005			5
97	An update on the genetics of dementia with Lewy bodies. <b>2017</b> , 43, 1-8			22
96	Current Proteomic Approaches Applied to Brain Function. <i>Neuromethods</i> , <b>2017</b> ,	0.4		3

95	Proteomics Coupled with Metabolite and Cell Wall Profiling Reveal Metabolic Processes of a Developing Rice Stem Internode. <b>2017</b> , 8, 1134		12
94	A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182098	3.7	30
93	An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. <b>2017</b> , 10, 36		18
92	Quantitative Proteomic Analysis Reveals Synaptic Dysfunction in the Amygdala of Rats Susceptible to Chronic Mild Stress. <i>Neuroscience</i> , <b>2018</b> , 376, 24-39	3.9	13
91	Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. <b>2018</b> , 8, 2098		18
90	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <b>2018</b> , 141, 582-595		100
89	Multiplex biosensing with highly sensitive magnetic nanoparticle quantification method. <b>2018</b> , 459, 260-264		34
88	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. <b>2018</b> , 12, 1700131		62
87	A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers. <b>2018</b> , 101, 96-102		68
86	Computational systems biology approaches for Parkinson's disease. <b>2018</b> , 373, 91-109		12
85	Protein variability in cerebrospinal fluid and its possible implications for neurological protein biomarker research. <i>PLoS ONE</i> , <b>2018</b> , 13, e0206478	3.7	17
84	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. <b>2018</b> , 10, 98		19
83	Characterization of Cerebrospinal Fluid via Data-Independent Acquisition Mass Spectrometry. <b>2018</b> , 17, 3418-3430		19
82	Proteomic approach to profiling immune complex antigens in cerebrospinal fluid samples from patients with central nervous system autoimmune diseases. <b>2018</b> , 484, 26-31		17
81	Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population. <b>2018</b> , 27, 1166-1173		15
80	Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond. <b>2019</b> , 38, 34-48		14
79	Cerebrospinal Fluid (CSF) Proteomics. <i>Methods in Molecular Biology</i> , <b>2019</b> ,	1.4	
78	Hippocampal proteomic changes of susceptibility and resilience to depression or anxiety in a rat model of chronic mild stress. <b>2019</b> , 9, 260		30

77	Cerebrospinal Fluid Proteomics For Identification Of $\alpha$ -Macroglobulin As A Potential Biomarker To Monitor Pharmacological Therapeutic Efficacy In Dopamine Dictated Disease States Of Parkinson's Disease And Schizophrenia. <b>2019</b> , 15, 2853-2867		5
76	Top-Down Proteomics Applied to Human Cerebrospinal Fluid. <i>Methods in Molecular Biology</i> , <b>2019</b> , 2044, 193-219	1.4	
75	Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions. <b>2019</b> , 39, 901-915		14
74	Neuropeptide PEN and Its Receptor GPR83: Distribution, Signaling, and Regulation. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 1884-1891	5.7	6
73	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 68, 537-550	4.3	5
72	Cerebrospinal fluid biomarker for Parkinson's disease: An overview. <b>2019</b> , 97, 60-66		22
71	Vitamin D basis of Alzheimer's disease: from genetics to biomarkers. <b>2019</b> , 18, 7-15		20
70	Integrative analysis of blood metabolomics and PET brain neuroimaging data for Parkinson's disease. <b>2019</b> , 124, 555-562		26
69	Embryonic cerebrospinal fluid formation and regulation. <b>2020</b> , 102, 3-12		8
68	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. <b>2020</b> , 57, 86-98		23
67	Secreted Chaperones in Neurodegeneration. <b>2020</b> , 12, 268		11
66	Gliome database: a comprehensive web-based tool to access and analyze glia secretome data. <b>2020</b> , 2020,		3
65	What Room for Two-Dimensional Gel-Based Proteomics in a Shotgun Proteomics World?. <b>2020</b> , 8,		21
64	Neuron-glia interactions: Molecular basis of alzheimer's disease and applications of neuroproteomics. <b>2020</b> , 52, 2931-2943		22
63	A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease. <i>Clinical Proteomics</i> , <b>2020</b> , 17, 21	5	21
62	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <b>2020</b> , 15, 36		16
61	Increased expression and retention of the secretory chaperone proSAAS following cell stress. <b>2020</b> , 25, 929-941		3
60	Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease. <b>2020</b> , 10, 2479		19

59	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <b>2020</b> , 16, 265-284	53
58	Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker. <b>2020</b> , 26, 193-205	3
57	Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. <b>2021</b> , 41, 1427-1473	26
56	Comparison of Serum Free and Bioavailable 25-Hydroxyvitamin D Levels in Alzheimer's Disease and Healthy Control Patients. <b>2021</b> , 52, 219-225	6
55	In-depth Site-specific Analysis of N-glycoproteome in Human Cerebrospinal Fluid and Glycosylation Landscape Changes in Alzheimer's Disease. <b>2021</b> , 20, 100081	12
54	Chronic mild stress-induced protein dysregulations correlated with susceptibility and resiliency to depression or anxiety revealed by quantitative proteomics of the rat prefrontal cortex. <b>2021</b> , 11, 143	3
53	Label-Free Liquid Chromatography-Mass Spectrometry Proteomic Analysis of Urinary Identification in Diabetic Vascular Dementia in a Han Chinese Population. <b>2021</b> , 13, 619945	2
52	Fibrinogen and Complement Factor H are promising CSF protein biomarker(s) for Parkinson's disease with cognitive impairment- A Proteomics and ELISA based study.	
51	Analysis of Chronic Mild Stress-Induced Hypothalamic Proteome: Identification of Protein Dysregulations Associated With Vulnerability and Resiliency to Depression or Anxiety. <b>2021</b> , 14, 633398	5
50	Proteomic characterization of secretory granules in dopaminergic neurons indicates chromogranin/secretogranin-mediated protein processing impairment in Parkinson's disease. <b>2021</b> , 13, 20335-20358	2
49	Global effects of RAB3GAP1 dysexpression on the proteome of mouse cortical neurons. <b>2021</b> , 53, 1339-1350	0
48	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. <b>2021</b> , 159, 211-233	8
47	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. <b>2021</b> , 10, 37	0
46	Proteomic Response of Rat Pituitary Under Chronic Mild Stress Reveals Insights Into Vulnerability and Resistance to Anxiety or Depression. <i>Frontiers in Genetics</i> , <b>2021</b> , 12, 751999	4.5 1
45	Age-associated changes in microglia and astrocytes ameliorate blood-brain barrier dysfunction. <i>Molecular Therapy - Nucleic Acids</i> , <b>2021</b> , 26, 970-986	10.7 1
44	Comparative Proteomics of Rat Olfactory Bulb Reveal Insights into Susceptibility and Resiliency to Chronic-stress-induced Depression or Anxiety. <i>Neuroscience</i> , <b>2021</b> , 473, 29-43	3.9 0
43	Quantification of the Trans-Synaptic Partners Neuroligin-Neurexin in CSF of Neurodegenerative Diseases by Parallel Reaction Monitoring Mass Spectrometry. <i>SSRN Electronic Journal</i> ,	1
42	Phase separation of proSAAS into spheres results in core sequestration of TDP-43	1

41	Serum Proteomic Profiling Analysis of Rats Chronically Exposed to Arsenic. <i>Medical Science Monitor</i> , <b>2019</b> , 25, 9923-9932	3.2	2
40	Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. <i>PLoS ONE</i> , <b>2011</b> , 6, e18850	3.7	168
39	Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. <i>PLoS ONE</i> , <b>2011</b> , 6, e26540	3.7	84
38	Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. <i>PLoS ONE</i> , <b>2013</b> , 8, e64314	3.7	31
37	High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer's Disease in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , <b>2015</b> , 10, e0135365	3.7	44
36	Analysis of the Cerebrospinal Fluid Proteome in Alzheimer's Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150672	3.7	56
35	A First Tetraplex Assay for the Simultaneous Quantification of Total $\beta$ Synuclein, Tau, $\beta$ Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153564	3.7	6
34	Emerging candidate biomarkers for Parkinson's disease: a review. <b>2014</b> , 5, 27-34		18
33	Hyphenated Mass Spectrometry Techniques in the Diagnosis of Amyloidosis. <i>Current Medicinal Chemistry</i> , <b>2019</b> , 26, 104-120	4.3	1
32	Proteomic Insights Into Susceptibility and Resistance to Chronic-Stress-Induced Depression or Anxiety in the Rat Striatum. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 730473	5.6	0
31	Proteomics as a New Tool for Biomarker-Discovery in Neuropsychiatric Disorders. <b>2009</b> , 103-111		
30	Proteomic Discovery of Biomarkers in the Cerebrospinal Fluid of Brain Tumor Patients. <b>2009</b> , 577-613		1
29	The Future Role of Biomarkers in Alzheimer's Disease Diagnostics. <b>2013</b> , 231-248		
28	Cardiovascular Proteomic Analysis. <b>2013</b> , 81-98		
27	Lipid Peroxidation and Age-Related Neurodegenerative Disorders. <b>2015</b> , 350-383		
26	Statistical Aspects in Proteomic Biomarker Discovery. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1362, 293-310	1.4	
25	Integration of Transcriptomic and Proteomic Data for Disease Insights. <i>Neuromethods</i> , <b>2017</b> , 325-356	0.4	
24	Receptores neurais e a doena de Alzheimer: uma reviso sistemtica da literatura sobre as famlias de receptores mais associadas a doena, suas funes e formas de expresso. <i>Jornal Brasileiro De Psiquiatria</i> , <b>2019</b> , 68, 161-176	0.5	2

23	Discovery of plasma protein biomarkers related to Alzheimer's disease, sex and APOE genotype.		0
22	An unconventional cerebrospinal fluid-derived Semaphorin-signalling regulates apical progenitor dynamics in the developing neocortex.		2
21	Mass spectrometry-based proteomics and peptidomics for biomarker discovery in neurodegenerative diseases. <i>International Journal of Clinical and Experimental Pathology</i> , <b>2009</b> , 2, 132-48	1.4	10
20	Alzheimer's disease biomarkers in animal models: closing the translational gap. <i>American Journal of Neurodegenerative Disease</i> , <b>2013</b> , 2, 108-20	2.5	13
19	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry.. <i>EBioMedicine</i> , <b>2022</b> , 75, 103793	8.8	0
18	Proteomics Principles and Clinical Applications. <b>2022</b> , 67-76		0
17	Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer's disease.. <i>Proteome Science</i> , <b>2022</b> , 20, 2	2.6	1
16	Saudi physicians' perceptions of the validity of autopsy and its implications - Structural equation modeling.. <i>Journal of Clinical Forensic and Legal Medicine</i> , <b>2022</b> , 86, 102320	1.7	
15	Fibrinogen and Complement Factor H Are Promising CSF Protein Biomarkers for Parkinson's Disease with Cognitive Impairment-A Proteomics-ELISA-Based Study.. <i>ACS Chemical Neuroscience</i> , <b>2022</b> ,	5.7	
14	Fundamentals of Biostatistics. 28-41		
13	Selecting Outcome Measures. 69-77		
12	CHAPTER 13. Biomarkers of Oxidative Stress in Parkinson's Disease. <i>Issues in Toxicology</i> , 423-446	0.3	
11	Sequestration of TDP-43 Aggregates by Cytoplasmic Expression of the proSAAS Chaperone.. <i>ACS Chemical Neuroscience</i> , <b>2022</b> ,	5.7	0
10	Endosomal-Lysosomal and Autophagy Pathway in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , <b>2022</b> , 1-14	4.3	0
9	Many kinds of oxidized proteins are present more in the urine of the elderly. <i>Clinical Proteomics</i> , <b>2022</b> , 19,	5	
8	Proteomics as a Potential Tool for Biomarker Discovery. <b>2022</b> , 119-141		
7	Exogenous Tetranectin Alleviates Pre-formed-fibrils-induced Synucleinopathies in SH-SY5Y Cells by Activating the Plasminogen Activation System.		
6	Boost-DiLeu: Enhanced Isobaric N,N-Dimethyl Leucine Tagging Strategy for a Comprehensive Quantitative Glycoproteomic Analysis.		0

- 5 The Use of Proteomics in Dementia with Lewy Bodies From Protein Biomarkers to Proteomics in Dementia with Lewy Bodies 2022, 101771 ○
- 4 A balance of noncanonical Semaphorin signaling from the cerebrospinal fluid regulates apical cell dynamics during corticogenesis. 2022, 8, ○
- 3 Urinary protein biomarkers based on LCMS/MS analysis to discriminate vascular dementia from Alzheimer disease in Han Chinese population. 15, ○
- 2 Proteomics of the astrocyte secretome reveals changes in their response to soluble oligomeric A $\beta$  ○
- 1 Lipidomics and proteomics: An integrative approach for early diagnosis of dementia and Alzheimer disease. 14, ○